Eribulin for A/MBC in China

For this retrospective cohort study, data were retrieved from the electronic medical records (eMRs) of patients with A/MBC treated with eribulin at China Medical University Hospital (CMUH) between 1 January 2015 and 30 June 2019. Female patients with locally recurrent or metastatic breast cancer, age ≥ 20 years and who received at least one cycle of eribulin for A/MBC were included. Patients with a second cancer or who did not have complete blood counts at the initiation of eribulin treatment or at 1, 3 and 6 months following eribulin initiation were excluded for further analysis.

Free full text: Click here

Su M.X., Lin H.W., Nguyen H.T., Lin T.C., Chen C.J., Wang H.C., Wu C.T., Wu Y.C., He G.Y., Liu L.C, & Huang C.H. (2024). Monitoring trends in the absolute lymphocyte count and the neutrophil-to-lymphocyte ratio in patients with breast cancer receiving eribulin. BMC Cancer, 24, 195.

Publication 2024

Corresponding Organization :

Other organizations : China Medical University, China Medical University Hospital

Top 5 similar protocols

Variable analysis

independent variables

Eribulin treatment for A/MBC

dependent variables

Overall survival
Progression-free survival

control variables

Age ≥ 20 years
Complete blood counts at the initiation of eribulin treatment and at 1, 3 and 6 months following eribulin initiation

notes

The independent variable is the eribulin treatment for A/MBC, as this is the intervention being studied.
The dependent variables are the overall survival and progression-free survival, as these are the measured outcomes.
The control variables are the age of patients (≥ 20 years) and the requirement for complete blood counts at specific time points, as these are used to ensure valid results by controlling for potential confounding factors.
No other variables were explicitly mentioned in the provided information.

Annotations

Based on most similar protocols

Etiam vel ipsum. Morbi facilisis vestibulum nisl. Praesent cursus laoreet felis. Integer adipiscing pretium orci. Nulla facilisi. Quisque posuere bibendum purus. Nulla quam mauris, cursus eget, convallis ac, molestie non, enim. Aliquam congue. Quisque sagittis nonummy sapien. Proin molestie sem vitae urna. Maecenas lorem.

As authors may omit details in methods from publication, our AI will look for missing critical information across the 5 most similar protocols.

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!